Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | MSH6 negative |
Therapy | Ipilimumab + Nivolumab |
Indication/Tumor Type | prostate adenocarcinoma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
MSH6 negative | prostate adenocarcinoma | predicted - sensitive | Ipilimumab + Nivolumab | Case Reports/Case Series | Actionable | In a Phase II trial (INSPIRE), treatment with Yervoy (ipilimumab) and Opdivo (nivolumab) in patients with metastatic prostate adenocarcinoma resulted in a disease control rate (DCR) at 6 mo of 38%, objective response rate (ORR) of 38% (14/37), and median progression-free survival (mPFS) of 4.0 mo in the overall efficacy cohort, and a DCR at 6 mo of 81%, ORR of 75% (9/12, all partial responses), and mPFS or 32.7 mo in patients with mismatch repair deficiency (dMMR) (PMID: 39293514). | 39293514 |
PubMed Id | Reference Title | Details |
---|---|---|
(39293514) | Ipilimumab with Nivolumab in molecular-Selected patients with castration-resistant PRostate cancer: primary analysis of the Phase 2 INSPIRE trial. | Full reference... |